Everyone’s 39 trillion of bacteria, our opportunity for tomorrow’s human microbiome therapeutics.

More informations

Passio Human Microbiome

Microbiome science,

                  tomorrow’s healthcare

We are moving beyond one speciality.

We are the only microbiome company developing microbiome therapeutics for GDM.

We are the team of multidisciplinary specialists dedicated to extraordinary challenges.

Our focus areas:

Inflammatory Bowel diseaseis a group of gastrointestinal inflammatory diseases which mainly comprises of Ulcerative colitis and Crohn’s disease. Inflammatory bowel diseases cause long terms chronic as well as severe inflammation in gastrointestinal tract without any known cause.

Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. Today the number of people with diabetes exceeded 422 million, it is forecasted that until 2035 this number will increase up to ½ billion. Globally, 10 times more people are living with diabetes than with HIV.

Asthma is a common long-term inflammatory disease of the airways of the lungs. It is characterized by variable and recurring symptoms, reversible airflow obstruction and easily triggered bronchospasms. Asthma affects all ages but frequently begins in childhood.

Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. The disease accounts for 7.4 million deaths worldwide. 600k deaths each month are attributed to cancer. Nearly 1 in 3 cancers could be prevented by eating well, moving more, and staying lean. ½ of people don’t know that they established cancer risks (inactivity, obesity, diets low in fruits and vegetables, red and processed meats, alcohol).


Passio Human Microbiome, founded in 2016, is a comprehensive research center focused on the study of the microbiome and its impact on human health. We lead broad microbiome research across a range of therapeutic areas. We are the only microbiome company developing microbiome therapeutic for Gestational Diabetes Mellitus, GDM.


Our scientists combine science, translational medicine, and use powerful fields such as genomics, epigenomics, transcriptomics, proteomics, metabolomics and microfiometry, as well as bioinformatics to answer important questions about the microbiome. The aim is to use our strengths and the emerging possibilities of expanding the scope of research related to the microbiome. We are extremely proud of the fact that we conduct key research in the field of cancer therapy support, which results in Meliotic.


We develop non-invasive ways to monitor patients for signs of disease and precise methods to manipulate the microbiome to restore health. We do this by supporting translation studies designed to positively influence patients’ lives and collaborate on clinical trials to show how the microbiome affects human physiology, immune systems, metabolisms and disease progression. Supporting all our efforts is possible thanks to the multidisciplinary team, a specialized research center and careful data analysis.


power that delivers therapies

The changing relationship between the gut microbiota and the human host throughout life offers a series of time windows for therapeutic intervention. Microbiome consists trillions of bacteria which colonise the human gut. It is crucial in shaping the host immune system & metabolism. Microbiome has 100x as many genes as the human genome and almost 95% of our microbiota is located in the GI tract. What’s interesting, the gut microbiota can weight up to 2 kg and the human body has more microbes than there are stars in the milky way. Moreover, each person has a unique gut microbiota, as individual as a fingerprint and about 90% of disease can be linked in some way back to the gut and health of the microbiome.

We are constantly looking to explore new microbiome opportunities, improve our solutions and transform science into pipelines. Therefore, we are open to partnerships.